Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on August 18, 2021. The filing discloses the entry into a material definitive agreement and related press release regarding a new strategic partnership.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses exclusively on the terms of a new licensing agreement.
Material Changes and Agreements
On August 18, 2021, the Company entered into a License Agreement and a Basic Sale and Purchase Agreement with Wakamoto Pharmaceutical Co., Ltd. Key terms include:
- Exclusive Rights: Wakamoto granted Harrow exclusive license and marketing rights for its ophthalmic drug candidate, MAQ-100, in the U.S. and Canada.
- Supply and Pricing: Wakamoto will supply MAQ-100 to Harrow at a per-unit transfer price.
- Milestone Payments: Harrow is obligated to pay up to $2,000,000 in regulatory milestones and up to $6,200,000 in commercial milestones.
- Regulatory Responsibility: Harrow is responsible for regulatory filings and fees for MAQ-100 in the designated territories.
- Term: The agreement term is five years from FDA market approval, with an option for a five-year extension if certain unit sales thresholds are met.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future performance. The primary contingency noted is the achievement of regulatory approval by the FDA and the subsequent meeting of unit sales thresholds to extend the agreement term. The full text of the agreements is expected to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2021.
Investor Verification Checklist
- Verify the specific per-unit transfer price for MAQ-100 supply in the full agreement text.
- Confirm the exact regulatory and commercial milestones triggering the $8.2 million in potential payments.
- Review the current development status and FDA approval timeline for MAQ-100.
- Assess the impact of the new agreement on the Company's cash flow requirements for regulatory filings.